|
|
|
 |
|
製品情報 - Reference Compounds
|
GDC-0068(RG7440)
| カタログ : |
C13704 |
| 製品の名前: |
GDC-0068(RG7440) |
| 化学の名前: |
(2S)-2-(4-Chlorophenyl)-1-[4-[(5R,7R)-6,7-dihydro-7-hydroxy-5-methyl-5H-cyclopentapyrimidin-4-yl]-1-piperazinyl]-3-[(1-methylethyl)amino]-1-propanone;(S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one |
| CASナンバー : |
1001264-89-6 |
| 構成 : |
|
| 分子式: |
C24H32ClN5O2 |
| 分子量: |
458.00 |
| 外観: |
White Solid |
| 純度: |
>98% |
| 使い方: |
GDC-0068 is a novel, highly selective oral ATP-competitive inhibitor designed to bind to the 3 isoforms of Akt. GDC-0068 is being developed in collaboration with Array BioPharma.In preclinical studies, GDC-0068 induced growth arrest and cell death in certain cancer cell lines, and demonstrated robust antitumor activity in a range of cancer xenograft models, especially those with activation of the PI3K/Akt/mTOR pathway. GDC-0068 targets activated Akt and exhibits enhanced potency on mutant Akt1.GDC-0068 inhibits the growth and proliferation of cancer cell lines and xenograft models, including those with loss of PTEN function, oncogenic mutations in PIK3CA, and amplification of HER2. |
|
| 制品、有效に関する特許保護を売却せず、国家、売却こうした製品の特許侵害金人で、それは私たちの知らない特許の情况は全ての国、特許侵害責任は、十分に理解できるをバイヤーのリスクを高める. |
|
|
